192 related articles for article (PubMed ID: 33647840)
1. Potential of substituted quinazolines to interact with multiple targets in the treatment of cancer.
Choudhary S; Doshi A; Luckett-Chastain L; Ihnat M; Hamel E; Mooberry SL; Gangjee A
Bioorg Med Chem; 2021 Apr; 35():116061. PubMed ID: 33647840
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and biological evaluation of novel 4-anilinoquinazoline derivatives as hypoxia-selective EGFR and VEGFR-2 dual inhibitors.
Wei H; Duan Y; Gou W; Cui J; Ning H; Li D; Qin Y; Liu Q; Li Y
Eur J Med Chem; 2019 Nov; 181():111552. PubMed ID: 31387063
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and preclinical evaluation of 5-methyl-N
Devambatla RKV; Choudhary S; Ihnat M; Hamel E; Mooberry SL; Gangjee A
Bioorg Med Chem Lett; 2018 Oct; 28(18):3085-3093. PubMed ID: 30098869
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of tumor cell growth and angiogenesis by 7-aminoalkoxy-4-aryloxy-quinazoline ureas, a novel series of multi-tyrosine kinase inhibitors.
Ravez S; Barczyk A; Six P; Cagnon A; Garofalo A; Goossens L; Depreux P
Eur J Med Chem; 2014 May; 79():369-81. PubMed ID: 24747748
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, Molecular Modeling and Biological Evaluation of 4-Alkoxyquinazoline Derivatives as Novel Inhibitors of VEGFR2.
Lu L; Zhao TT; Liu TB; Sun WX; Xu C; Li DD; Zhu HL
Chem Pharm Bull (Tokyo); 2016 Nov; 64(11):1570-1575. PubMed ID: 27568484
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, Anticancer Screening of Some Novel Trimethoxy Quinazolines and VEGFR2, EGFR Tyrosine Kinase Inhibitors Assay; Molecular Docking Studies.
Altamimi AS; El-Azab AS; Abdelhamid SG; Alamri MA; Bayoumi AH; Alqahtani SM; Alabbas AB; Altharawi AI; Alossaimi MA; Mohamed MA
Molecules; 2021 May; 26(10):. PubMed ID: 34069962
[TBL] [Abstract][Full Text] [Related]
7. Molecular modelling and synthesis of quinazoline-based compounds as potential antiproliferative agents.
Yassen AS; Elshihawy HE; Said MM; Abouzid KA
Chem Pharm Bull (Tokyo); 2014; 62(5):454-66. PubMed ID: 24789927
[TBL] [Abstract][Full Text] [Related]
8. Novel promising 4-anilinoquinazoline-based derivatives as multi-target RTKs inhibitors: Design, molecular docking, synthesis, and antitumor activities in vitro and vivo.
Xu P; Chu J; Li Y; Wang Y; He Y; Qi C; Chang J
Bioorg Med Chem; 2019 Oct; 27(20):114938. PubMed ID: 31488358
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, biological evaluation and docking study of novel quinazoline derivatives as EGFR-TK inhibitors.
Jin H; Wu BX; Zheng Q; Hu CH; Tang XZ; Zhang W; Rao GW
Future Med Chem; 2021 Apr; 13(7):601-612. PubMed ID: 33685233
[No Abstract] [Full Text] [Related]
10. 4-Anilinoquinazoline Derivatives with Epidermal Growth Factor Receptor Inhibitor Activity.
Liu F; Tang B; Liu H; Li L; Liu G; Cheng Y; Xu Y; Chen W; Huang Y
Anticancer Agents Med Chem; 2016; 16(12):1652-1664. PubMed ID: 27039919
[TBL] [Abstract][Full Text] [Related]
11. Quinazoline-based multi-tyrosine kinase inhibitors: synthesis, modeling, antitumor and antiangiogenic properties.
Conconi MT; Marzaro G; Urbani L; Zanusso I; Di Liddo R; Castagliuolo I; Brun P; Tonus F; Ferrarese A; Guiotto A; Chilin A
Eur J Med Chem; 2013 Sep; 67():373-83. PubMed ID: 23900004
[TBL] [Abstract][Full Text] [Related]
12. Design and Synthesis of some new 2,4,6-trisubstituted quinazoline EGFR inhibitors as targeted anticancer agents.
Allam HA; Aly EE; Farouk AKBAW; El Kerdawy AM; Rashwan E; Abbass SES
Bioorg Chem; 2020 May; 98():103726. PubMed ID: 32171987
[TBL] [Abstract][Full Text] [Related]
13. Quinazoline-urea, new protein kinase inhibitors in treatment of prostate cancer.
Garofalo A; Goossens L; Lemoine A; Farce A; Arlot Y; Depreux P
J Enzyme Inhib Med Chem; 2010 Apr; 25(2):158-71. PubMed ID: 20222760
[TBL] [Abstract][Full Text] [Related]
14. Discovery of novel VEGFR-2 inhibitors embedding 6,7-dimethoxyquinazoline and diarylamide fragments.
Wang R; Liu H; You YY; Wang XY; Lv BB; Cao LQ; Xue JY; Xu YG; Shi L
Bioorg Med Chem Lett; 2021 Mar; 36():127788. PubMed ID: 33460739
[TBL] [Abstract][Full Text] [Related]
15. Pharmacophore based drug design and synthesis of oxindole bearing hybrid as anticancer agents.
Pathak A; Pandey V; Raj Pokharel Y; Devaraji V; Ali A; Haider K; Saad S; Dewangan RP; Siddiqui N; Shahar Yar M
Bioorg Chem; 2021 Nov; 116():105358. PubMed ID: 34544029
[TBL] [Abstract][Full Text] [Related]
16. Novel scaffold hopping of potent benzothiazole and isatin analogues linked to 1,2,3-triazole fragment that mimic quinazoline epidermal growth factor receptor inhibitors: Synthesis, antitumor and mechanistic analyses.
Rezki N; Almehmadi MA; Ihmaid S; Shehata AM; Omar AM; Ahmed HEA; Aouad MR
Bioorg Chem; 2020 Oct; 103():104133. PubMed ID: 32745759
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of 4-aniline quinazoline derivatives conjugated with hydrogen sulfide (H
Zheng YG; Zhang WQ; Meng L; Wu XQ; Zhang L; An L; Li CL; Gao CY; Xu L; Liu Y
Eur J Med Chem; 2020 Sep; 202():112522. PubMed ID: 32619886
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, biological evaluation, and molecular docking of new series of antitumor and apoptosis inducers designed as VEGFR-2 inhibitors.
Abdallah AE; Mabrouk RR; Al Ward MMS; Eissa SI; Elkaeed EB; Mehany ABM; Abo-Saif MA; El-Feky OA; Alesawy MS; El-Zahabi MA
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):573-591. PubMed ID: 35012403
[TBL] [Abstract][Full Text] [Related]
19. Discovery of 6-substituted 4-anilinoquinazolines with dioxygenated rings as novel EGFR tyrosine kinase inhibitors.
Li DD; Fang F; Li JR; Du QR; Sun J; Gong HB; Zhu HL
Bioorg Med Chem Lett; 2012 Sep; 22(18):5870-5. PubMed ID: 22901387
[TBL] [Abstract][Full Text] [Related]
20. Click chemistry for improvement in selectivity of quinazoline-based kinase inhibitors for mutant epidermal growth factor receptors.
Song J; Jang S; Lee JW; Jung D; Lee S; Min KH
Bioorg Med Chem Lett; 2019 Feb; 29(3):477-480. PubMed ID: 30554954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]